{
    "clinical_study": {
        "@rank": "153132", 
        "acronym": "TRAP", 
        "arm_group": {
            "arm_group_label": "ADI-PEG 20", 
            "arm_group_type": "Experimental", 
            "description": "Arginine deiminase formulated with polyethylene glycol"
        }, 
        "brief_summary": {
            "textblock": "A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in\n      patients with histologically proven advanced MPM, advanced peritoneal mesothelioma (for dose\n      escalation cohort only) or non-squamous NSCLC (stage IIIB/IV)."
        }, 
        "brief_title": "Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pleural Mesothelioma Malignant Advanced", 
            "Peritoneal Mesothelioma Malignant Advanced", 
            "Non-squamous Non-small Cell Lung Carcinoma Stage IIIB/IV (NSCLC)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Mesothelioma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Weekly ADI-PEG 20 will be cohort dose escalated (18, 27 and 36 mg/m2), with pemetrexed 500\n      mg/m2 and cisplatin 75 mg/m2 both given every 3 weeks. Subjects may receive a maximum of 6 -\n      3 week cycles of ADIPemCis for a total of 18 weeks of treatment. Those subjects completing\n      18 weeks may continue on ADI-PEG 20 monotherapy if they have SD or better."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven advanced MPM, advanced peritoneal mesothelioma (for dose\n             escalation cohort only) or non-squamous NSCLC (stage IIIB/IV)\n\n          -  Subjects with EGFR mutant NSCLC must have had an EGFR tyrosine kinase inhibitor (TKI)\n             and progressed or been shown to be intolerant of therapy\n\n          -  Subjects must be treatment na\u00efve to systemic chemotherapy (i.e., ADI-PEG 20 +\n             pemetrexed + cisplatin will be first-line systemic chemotherapy)\n\n          -  ASS1 deficiency using immunohistochemistry (IHC) demonstrated on tissue biopsy\n\n          -  ECOG PS 0-1\n\n          -  Expected survival of at least 3 months\n\n          -  Age 18 years or over (there is no upper age limit)\n\n          -  Evaluable disease by modified RECIST criteria for MPM and RECIST 1.1 criteria for\n             non-squamous NSCLC\n\n          -  Written (signed and dated) informed consent and must be capable of co-operating with\n             treatment and follow up\n\n          -  Adequate hematologic, hepatic, and renal function\n\n        Exclusion Criteria:\n\n          -  Radiotherapy (except for palliative reasons), EGFR, TKI, ALK inhibitor or\n             immunotherapy the previous four weeks before study treatment.\n\n          -  Ongoing toxic manifestations of previous treatments.  Exceptions to this are alopecia\n             or certain Grade 1 toxicities, which in the opinion of the Investigator are stable\n             and with the trial sponsor approval should not exclude the patient\n\n          -  Symptomatic brain (patients must be stable for > 1 month post radiotherapy or\n             surgery) or spinal cord metastases\n\n          -  Major thoracic or abdominal surgery from which the patient has not yet recovered\n\n          -  Therapeutic anticoagulation (prophylactic dose low molecular weight heparin is\n             acceptable)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029690", 
            "org_study_id": "POLARIS2013-006"
        }, 
        "intervention": {
            "arm_group_label": "ADI-PEG 20", 
            "intervention_name": "ADI-PEG 20", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pemetrexed", 
                "Cisplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "argininosuccinate synthetase", 
            "arginine", 
            "arginine deiminase"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "contact": {
                "email": "p.w.szlosarek@qmul.ac.uk", 
                "last_name": "Peter Szlosarek, MD, PhD"
            }, 
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "state": "England", 
                    "zip": "EC1M 6BQ"
                }, 
                "name": "Centre for Experimental Cancer Medicine (CECM)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)", 
        "overall_contact": {
            "email": "jbomalaski@polarispharma.com", 
            "last_name": "John Bomalaski, MD", 
            "phone": "858-452-6688", 
            "phone_ext": "114"
        }, 
        "overall_official": {
            "affiliation": "Barts Cancer Institute", 
            "last_name": "Peter Szlosarek, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Determine preliminary estimates of efficacy, measured by modified RECIST criteria for MPM and RECIST 1.1 criteria for non-squamous NSCLC, for ADI-PEG 20 in combination with pemetrexed and cisplatin", 
            "safety_issue": "Yes", 
            "time_frame": "18 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029690"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Determine the MTD of ADI-PEG 20 in combination with pemetrexed and cisplatin", 
            "safety_issue": "No", 
            "time_frame": "18 weeks"
        }, 
        "source": "Polaris Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Polaris Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}